Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H48J | ISIN: SE0009973563 | Ticker-Symbol: 6XP
Stuttgart
04.11.24
08:21 Uhr
5,060 Euro
-0,020
-0,39 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XSPRAY PHARMA AB Chart 1 Jahr
5-Tage-Chart
XSPRAY PHARMA AB 5-Tage-Chart
GlobeNewswire (Europe)
152 Leser
Artikel bewerten:
(1)

XSpray Pharma AB: Interim Report First Quarter 2024

January-March 2024, Group

  • Net sales amounted to SEK 0 thousand (0)
  • Loss before tax amounted to SEK -67,781 thousand (-34,827)
  • Earnings per share before dilution amounted to SEK -2.17 (-1.54)
  • Cash flow from operating activities amounted to SEK -55,311 thousand (-45,535)
  • Cash flow from investing activities amounted to SEK -5,149 thousand (-14,650)

Significant events during the quarter

  • Xspray Pharma appointed Michael af Winklerfelt as acting CFO, starting on February 8.
  • In January 2024, Xspray Pharma submitted additional information for its New Drug Application for Dasynoc® following a Complete Response Letter from the FDA. Xspray Pharma was assigned a PDUFA date, July 31, 2024, by the FDA, which refers to the FDA's deadline for completing the approval process of Dasynoc®.

Significant events after the end of the reporting period

  • Xspray Pharma received declarations of intent whereby owners of approximately 62 percent of shares in the company stated their intent to subscribe for newly issued shares with their outstanding TO6 warrants.
  • Xspray Pharma announced its fourth product candidate, XS025 (previously designated XS015) for clinical study. XS025 will be based on the active substance cabozantinib, which is used in renal cell carcinoma and other cancers. This initiative targets the US market for cabozantinib, which is projects to reach approximately USD 2.3 billion by 2026.
  • Xspray Pharma announced the outcome of exercised warrants of series TO6. In total, 2,508,723 series TO6-warrants were exercised to subscribe for the same number of new shares. Xspray Pharma thereby received proceeds of SEK 100.3 million before transaction costs. Proceeds will be used for the US launch of the company's first product, Dasynoc®, as well as for continued development of other product candidates in the company's portfolio.
  • The shareholders of Xspray Pharma AB are summoned to the annual general meeting on Tuesday 21 May 2024 at 10.00 CET at Advokatfirman Vinge's office on Smålandsgatan 20 in Stockholm

"We are continuing to make important preparations for the launch of our first product - Dasynoc®. This is an improved version of a well-established drug for the treatment of leukemia (CML and ALL). Dasynoc® has shown distinct clinical benefits through lower dosage requirements and lower variability in absorption, and the ability to be co-medicated with commonly used gastric acid suppressants. Existing treatments have major problems with co-medication for gastric ulcers, making Dasynoc® poised to offer vital patient benefits. Alongside the clinical arguments, during the period we produced compelling health economic data showing how Dasynoc® can lower the overall healthcare costs for patients - an extremely strong message to the US insurance companies concerned.

Together with our commercial partner, EVERSANA, we are creating a basis for a rapid and robust launch of Dasynoc®. In parallel, we are building the infrastructure for bringing forthcoming products that are based on our platform technology to market.

During the quarter, we submitted additional information for our New Drug Application (NDA) for Dasynoc® to the FDA. Subsequently, the FDA issued a PDUFA date: July 31, 2024, which is the FDA's own deadline for a decision on the marketing approval process for Dasynoc®. After the end of the period, we announced that we are ready to advance our fourth product candidate, XS025 (previously designated XS015) cabozantinib, into clinical study - our additional product candidate for the treatment of renal cancer. We also strengthened our cash holdings ahead of the final phase of our planned launch through the TO6 program, which has been subscribed at a rate of 80 percent and raised SEK 100 million before issue expenses." - Per Andersson CEO, Xspray Pharma

For further information, please contact:

Kerstin Hasselgren
Senior Advisor & Investor Relations
Xspray Pharma AB
Mob: +46 (0) 70 311 16 83
E-mail: kerstin.hasselgren@xspray.com

About Xspray Pharma

About Xspray Pharma AB
Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit www.xspraypharma.com.

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.